CLINICAL OUTCOME AND PROGNOSIS IN 49 PATIENTS WITH MANTLE CELL LYMPHOMA TREATED WITH ROUTINE CLINICAL PRACTICE
(Abstract release date: 05/19/16)
EHA Library. Tumyan G. 06/09/16; 134645; PB1745
Prof. Dr. Gayane Tumyan
Contributions
Contributions
Abstract
Abstract: PB1745
Type: Publication Only
Background
Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin’s lymphoma (NHL) that has commonly an aggressive clinical course and a poor prognosis. Current frontline intensive therapies have improved the outcome for patients (pts). Although these regimens have high response rates, most pts eventually have a relapse. There is not always possible to find a relationship between the intensity of treatment and survival outcomes of pts with MCL.
Aims
To assess the impact of treatment intensity on survival outcomes in newly diagnosed patients with MCL.
Methods
We conducted a retrospective analysis for pts with MCL diagnosed between 2004 and 2014 through our institutional databases. Frontline treatment modalities were categorized into 2 groups: high intensity (R-HyperCVAD or equivalent and/or stem cell transplant) and moderate intensity therapy (R-CHOP, R-B or equivalent). Median progression free survival (PFS) and overall survival (OS) for each treatment group were estimated using the Kaplan-Meier (KM) method and compared using the log rank test. Cox regression was used to identify univariate predictors of survival.
Results
A total of 49 pts MCL were identified. Median age was 58 yrs (31-78), 69% were male, 94% had advance stages and 59% bone marrow involvement; MIPI low (54%), int. (26%), high (20%). High and moderate intensity treatment accounted for 19 (39%) and 30 (61%) of pts. 53% pts in moderate group followed by R maintenance. Intensively treated patients were more likely to be young and have B symptoms (58% vs 20% respectively). With a median follow-up of 48 months, median PFS was 42 mos and OS not yet reached. Despite median duration of response with high and moderate intensity treatment was 57 mos vs 30 mos, there was no statistically significant difference in PFS (p=0,46) and OS (p=0,16) by treatment strategy. This lack of survival difference was true for all pairwise log-rank comparisons between treatment groups. No significant correlation with OS was observed with age (p=0,56), MIPI risk (p=0,13), or treatment intensity (p=0.30).
Conclusion
In our retrospective analysis, we were not able to validate the hypothesis, that frontline intensive treatment may improve OS in MCL. These data highlight the lack of a 'standard of care' in MCL, and provide further rationale for the use of novel agents in newly diagnosed MCL.
Session topic: E-poster
Keyword(s): Mantle cell lymphoma, Treatment
Type: Publication Only
Background
Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin’s lymphoma (NHL) that has commonly an aggressive clinical course and a poor prognosis. Current frontline intensive therapies have improved the outcome for patients (pts). Although these regimens have high response rates, most pts eventually have a relapse. There is not always possible to find a relationship between the intensity of treatment and survival outcomes of pts with MCL.
Aims
To assess the impact of treatment intensity on survival outcomes in newly diagnosed patients with MCL.
Methods
We conducted a retrospective analysis for pts with MCL diagnosed between 2004 and 2014 through our institutional databases. Frontline treatment modalities were categorized into 2 groups: high intensity (R-HyperCVAD or equivalent and/or stem cell transplant) and moderate intensity therapy (R-CHOP, R-B or equivalent). Median progression free survival (PFS) and overall survival (OS) for each treatment group were estimated using the Kaplan-Meier (KM) method and compared using the log rank test. Cox regression was used to identify univariate predictors of survival.
Results
A total of 49 pts MCL were identified. Median age was 58 yrs (31-78), 69% were male, 94% had advance stages and 59% bone marrow involvement; MIPI low (54%), int. (26%), high (20%). High and moderate intensity treatment accounted for 19 (39%) and 30 (61%) of pts. 53% pts in moderate group followed by R maintenance. Intensively treated patients were more likely to be young and have B symptoms (58% vs 20% respectively). With a median follow-up of 48 months, median PFS was 42 mos and OS not yet reached. Despite median duration of response with high and moderate intensity treatment was 57 mos vs 30 mos, there was no statistically significant difference in PFS (p=0,46) and OS (p=0,16) by treatment strategy. This lack of survival difference was true for all pairwise log-rank comparisons between treatment groups. No significant correlation with OS was observed with age (p=0,56), MIPI risk (p=0,13), or treatment intensity (p=0.30).
Conclusion
In our retrospective analysis, we were not able to validate the hypothesis, that frontline intensive treatment may improve OS in MCL. These data highlight the lack of a 'standard of care' in MCL, and provide further rationale for the use of novel agents in newly diagnosed MCL.
Session topic: E-poster
Keyword(s): Mantle cell lymphoma, Treatment
Abstract: PB1745
Type: Publication Only
Background
Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin’s lymphoma (NHL) that has commonly an aggressive clinical course and a poor prognosis. Current frontline intensive therapies have improved the outcome for patients (pts). Although these regimens have high response rates, most pts eventually have a relapse. There is not always possible to find a relationship between the intensity of treatment and survival outcomes of pts with MCL.
Aims
To assess the impact of treatment intensity on survival outcomes in newly diagnosed patients with MCL.
Methods
We conducted a retrospective analysis for pts with MCL diagnosed between 2004 and 2014 through our institutional databases. Frontline treatment modalities were categorized into 2 groups: high intensity (R-HyperCVAD or equivalent and/or stem cell transplant) and moderate intensity therapy (R-CHOP, R-B or equivalent). Median progression free survival (PFS) and overall survival (OS) for each treatment group were estimated using the Kaplan-Meier (KM) method and compared using the log rank test. Cox regression was used to identify univariate predictors of survival.
Results
A total of 49 pts MCL were identified. Median age was 58 yrs (31-78), 69% were male, 94% had advance stages and 59% bone marrow involvement; MIPI low (54%), int. (26%), high (20%). High and moderate intensity treatment accounted for 19 (39%) and 30 (61%) of pts. 53% pts in moderate group followed by R maintenance. Intensively treated patients were more likely to be young and have B symptoms (58% vs 20% respectively). With a median follow-up of 48 months, median PFS was 42 mos and OS not yet reached. Despite median duration of response with high and moderate intensity treatment was 57 mos vs 30 mos, there was no statistically significant difference in PFS (p=0,46) and OS (p=0,16) by treatment strategy. This lack of survival difference was true for all pairwise log-rank comparisons between treatment groups. No significant correlation with OS was observed with age (p=0,56), MIPI risk (p=0,13), or treatment intensity (p=0.30).
Conclusion
In our retrospective analysis, we were not able to validate the hypothesis, that frontline intensive treatment may improve OS in MCL. These data highlight the lack of a 'standard of care' in MCL, and provide further rationale for the use of novel agents in newly diagnosed MCL.
Session topic: E-poster
Keyword(s): Mantle cell lymphoma, Treatment
Type: Publication Only
Background
Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin’s lymphoma (NHL) that has commonly an aggressive clinical course and a poor prognosis. Current frontline intensive therapies have improved the outcome for patients (pts). Although these regimens have high response rates, most pts eventually have a relapse. There is not always possible to find a relationship between the intensity of treatment and survival outcomes of pts with MCL.
Aims
To assess the impact of treatment intensity on survival outcomes in newly diagnosed patients with MCL.
Methods
We conducted a retrospective analysis for pts with MCL diagnosed between 2004 and 2014 through our institutional databases. Frontline treatment modalities were categorized into 2 groups: high intensity (R-HyperCVAD or equivalent and/or stem cell transplant) and moderate intensity therapy (R-CHOP, R-B or equivalent). Median progression free survival (PFS) and overall survival (OS) for each treatment group were estimated using the Kaplan-Meier (KM) method and compared using the log rank test. Cox regression was used to identify univariate predictors of survival.
Results
A total of 49 pts MCL were identified. Median age was 58 yrs (31-78), 69% were male, 94% had advance stages and 59% bone marrow involvement; MIPI low (54%), int. (26%), high (20%). High and moderate intensity treatment accounted for 19 (39%) and 30 (61%) of pts. 53% pts in moderate group followed by R maintenance. Intensively treated patients were more likely to be young and have B symptoms (58% vs 20% respectively). With a median follow-up of 48 months, median PFS was 42 mos and OS not yet reached. Despite median duration of response with high and moderate intensity treatment was 57 mos vs 30 mos, there was no statistically significant difference in PFS (p=0,46) and OS (p=0,16) by treatment strategy. This lack of survival difference was true for all pairwise log-rank comparisons between treatment groups. No significant correlation with OS was observed with age (p=0,56), MIPI risk (p=0,13), or treatment intensity (p=0.30).
Conclusion
In our retrospective analysis, we were not able to validate the hypothesis, that frontline intensive treatment may improve OS in MCL. These data highlight the lack of a 'standard of care' in MCL, and provide further rationale for the use of novel agents in newly diagnosed MCL.
Session topic: E-poster
Keyword(s): Mantle cell lymphoma, Treatment
{{ help_message }}
{{filter}}